Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
about
Dietary Natural Products for Prevention and Treatment of Liver CancerEpithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinomaProliferation of sphere-forming hepatocellular carcinoma cells is suppressed in a medium without glucose and arginine, but with galactose and ornithine.Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells.CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis.Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinomaStromal cell-derived factor-1 (SDF-1) as a target in liver diseases.Sorafenib: A Review in Hepatocellular Carcinoma.A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.Deoxyelephantopin induces apoptosis in HepG2 cells via oxidative stress, NF-κB inhibition and mitochondrial dysfunction.Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.Combination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt.Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC.By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation.The Effect of Selective c-MET Inhibitor on Hepatocellular Carcinoma in the MET-Active, β-Catenin-Mutated Mouse Model.Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma.Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinomaHMQ-T-B10 induces human liver cell apoptosis by competitively targeting EphrinB2 and regulating its pathwayCurcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors
P2860
Q26765440-905734F8-4B2F-48DF-AA22-00FD0E05800FQ26849546-343FE9C8-68D8-4764-822B-324C970AF8F7Q33599232-6F103DCB-D93A-46DF-A16D-A4BC7260BBB4Q36316437-913AEC02-F992-4120-8C2C-02F79AA1AE11Q37701242-4A1C90AC-EA86-4497-A120-8E0F9A09F7FEQ37706317-B6C8F16F-99B4-4242-890B-B696F06563FDQ38719539-465F2913-A12E-4E62-B640-3E62A425DFA0Q38867913-048BF982-CE47-4C5D-9AD8-FC40F1399527Q39181337-31AAA8A9-D77A-40FF-BCCE-1E6F810D45BAQ41348794-44947FE0-33A3-46AB-8357-99A2E94B5BE5Q41651606-A9EADD70-EF5B-4B1F-8BE1-B13D32B0BB21Q41846145-1AA4A144-A948-458A-8E8F-51A35B98029FQ46489500-FD77558B-B3CB-4FAA-8CD0-927C53DF556DQ47135284-5B71A160-EC87-4AD0-BD45-88AB1643009EQ47135468-95D6FB81-6D49-4FD7-9526-BAAA3F2DA06FQ47161820-4120BD05-9D05-4F96-BD4A-AB1F40619339Q47387460-8AA03EB5-C7BF-49A0-B20E-4988955F479CQ47547759-B046C43B-C7AA-477E-B10B-79F7C4F9BC83Q47878727-AD6020EF-1494-47F5-8C4C-BA615DF31CEDQ48140297-A0FE3C55-1D85-43FE-9CFF-F6C61E435841Q48597130-47AF9A16-5E85-44E7-944B-5E5317DC6495Q50156185-67D7CDCA-40CF-4219-B26B-71BBFDED1CDAQ55434396-3EF48768-1D85-4CAD-8B04-EC7F136EF419Q58579029-4100644C-2793-4ADF-9AF5-5C276A02236DQ58738086-142E4721-4A87-4204-8024-13CE41984D4BQ58772394-8991ED30-F6AB-4A6C-9AD2-42A7749DFCDD
P2860
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Potential molecular, cellular ...... e in hepatocellular carcinoma.
@en
type
label
Potential molecular, cellular ...... e in hepatocellular carcinoma.
@en
prefLabel
Potential molecular, cellular ...... e in hepatocellular carcinoma.
@en
P2093
P1433
P1476
Potential molecular, cellular ...... e in hepatocellular carcinoma.
@en
P2093
Diyu Huang
Hanning Ying
Jiang Chen
Jinghua Liu
Senjun Zhou
P356
10.1016/J.CANLET.2015.06.019
P407
P577
2015-07-10T00:00:00Z